Introduction
Prions, which are responsible for transmissible spongiform encephalopathies in humans and animals, are unconventional infectious agents essentially composed of a modified host protein termed PrP (1) . One of the unusual features of prion infections is a long incubation period that precedes invasion of the CNS. The pathophysiological events occurring at this preclinical step influence subsequent neurological evolution and are, therefore, potential therapeutic targets. The natural history of the disease has been mainly studied in mouse experimental scrapie. Peripheral lymphoid organs are specific sites of scrapie agent replication outside the CNS (2, 3) . Their importance for neuroinvasion after inoculation at the periphery was suspected in light of the observation that splenectomy and other methods that reduce peripheral lymphoid structures delay the onset of clinical manifestations (4, 5) . B cell-deficient mice resist usual doses of scrapie agent (6) , which in fact may be related to impaired follicular dendritic cell (FDC) differentiation in those animals (7, 8) . Indeed, certain models of FDC deficiency (TNF-α gene disruption, or treatment with soluble recombinant lymphotoxin-β receptor [LTβR-Ig]) display resistance to scrapie (8) (9) (10) , whereas constitutive expression of cellular PrP on FDCs but not on lymphoid cells correlates with scrapie susceptibility (8) . Because PrP expression is required for replication of the scrapie agent (11) , FDCs are thought to be an essential site of amplification outside the nervous system. Nevertheless, the mechanisms of neuroinvasion remain obscure, and some observations suggest that involvement of another cell compartment could follow accumulation in the germinal centers of lymphoid organs. Recently, the involvement of cells other than FDCs, possibly of myeloid origin, has been put forward as a possible factor in prion neuroinvasion from the periphery (12) . When scrapie-infected mice were treated with LTβR-Ig, the pathological conformer of PrP (PrP Sc ) was shown to persist in the spleen in spite of the absence of FDCs (10) . In the present study, we tested the hypothesis that CD11c + dendritic cells, which are clearly distinct from FDCs based on their phenotype, location, and functions (13, 14) and are specialized in capturing and carrying antigens, might accumulate prions and transfer them to the CNS.
Transmissible spongiform encephalopathies display long incubation periods at the beginning of which the titer of infectious agents (prions) increases in peripheral lymphoid organs. This "replication" leads to a progressive invasion of the CNS. Follicular dendritic cells appear to support prion replication in lymphoid follicles. However, the subsequent steps of neuroinvasion remain obscure. CD11c + dendritic cells, an unrelated cell type, are candidate vectors for prion propagation. We found a high infectivity titer in splenic dendritic cells from prion-infected mice, suggesting that dendritic cells carry infection. To test this hypothesis, we injected RAG-1 0/0 mice intravenously with live spleen cell subsets from scrapie-infected donors. Injection of infected dendritic cells induced scrapie without accumulation of prions in the spleen. These results suggest that CD11c + dendritic cells can propagate prions from the periphery to the CNS in the absence of any additional lymphoid element.
It has been passaged serially by intracerebral injection of C57BL/6J female mice (The Jackson Laboratory, Bar Harbor, Maine, USA). At the time of clinical disease, brains were removed under sterile conditions and 10% homogenates were prepared in PBS. All homogenates were stored at -70°C before use. To obtain the spleens for cell fractionation, C57BL/6 female mice were injected intraperitoneally with 0.025 ml of a 1% homogenate of 139A-positive brain. Spleens were harvested 10-13 weeks after injection. Five of the injected mice were allowed to proceed to clinical disease, and the incubation period of 175 ± 3 days was that expected for the 139A strain in intraperitoneally injected C57BL/6 mice.
Cell subset fractionation. Spleens from 139A-infected mice were immediately injected with 3 ml of 1 mg/ml collagenase D (Boehringer Mannheim Biochemicals Inc., Mannheim, Germany) in PBS and then left to incubate 40 minutes at 37°C. After filtration on 100-µm mesh, mononuclear cells were obtained by centrifugation on Lympholyte-M (Cedarlane Laboratories Ltd., Hornby, Ontario, Canada) and washed with PBS containing 0.5% BSA and 2.5 mM sodium EDTA. All steps of magnetic cell sorting (MACS; Miltenyi Biotec, Auburn, California, USA) intracerebral were performed in this buffer. After blocking with 10% mouse serum for 20 minutes at room temperature, dendritic cells were enriched by positive selection with antiCD11c-conjugated magnetic particles according to the manufacturer's instructions. A B cell-enriched fraction was prepared by depleting the flow-through cells from the CD11c sorting with anti-CD90 and anti-CD43 magnetic particles. Total splenocytes as well as cell fractions were analyzed by cytofluorimetry using anti-B220, -CD3, -CD11c, and -CD11b phycoerythrin-or FITC-conjugated antibodies (PharMingen International, San Diego, California, USA).
Infectivity measurements. Serial tenfold dilutions of lysates from the various fractionated spleen cell preparations were injected intracerebrally (0.025 ml) into CD-1 mice and end-point titers determined. Titers were calculated by the Reed-Muench formula.
For confirming scrapie diagnosis, in seven recipient animals from the different groups (see below) sacrificed either at terminal scrapie or after sufficient incubation, presence of infectious agent was searched for by direct intracerebral passage of 0.025 ml of 1% brain homogenate into CD-1 mice (six to eight mice per inoculum).
Adoptive cell transfer. Immediately after fractionation, cells were washed and suspended in PBS (200 µl per injection), filtered on a 70-µm mesh, and injected intravenously in the tail of 8-week-old RAG-1 0/0 mice (The Jackson Laboratory). Animals received three consecutive injections at 1-week intervals of total mononuclear spleen cells (2 × 10 7 per injection), B cells (10 7 per injection), or CD11c + dendritic cells (10 6 per injection). In parallel, groups of mice were also inoculated intravenously with the same amounts of B cells or total mononuclear spleen cells that had been killed by three cycles of freezing and thawing. Because limited amounts of splenic CD11c + dendritic cells could be obtained, they were all injected as live cells.
Disease monitoring. Recipient RAG-1 0/0 mice were monitored weekly for clinical disease starting at 10 weeks after infection by observing their activity levels and competence on a set of parallel bars as described previously (16) . The scrapie incubation period was designated as the day on which the mouse had shown clinical symptoms for the third consecutive week. At this stage, they were within 1-4 weeks of death. Diagnosis of scrapie was confirmed by detection of PrP Sc and by intracerebral passage of 0.025 ml of 1% brain homogenate into CD-1 mice.
Detection of brain PrP Sc . One half brain sample from each animal was processed for PrP Sc isolation based on detergent insolubility, using the TL100 procedure as described previously (17) . Proteinase K was added to a concentration of 50 µg/ml and left to incubate for 10 minutes at room temperature. Approximately 0.075 brain equivalents of each brain sample, with or without previous proteinase K treatment, were deposited on 12% SDS-PAGE and analyzed by Western blot using polyclonal rabbit anti-PrP antiserum 78295 (18) .
Histology. Spleens were collected from sacrificed RAG-1 0/0 mouse recipients and cut in two parts. A small part was frozen for immunofluorescence studies, and the remaining part was fixed in paraformaldehyde. Fixed tissue sections (5 µm) were stained with hematoxylin and eosin. For PrP Sc detection, sections were treated by microwave heating (350 W for 30 minutes) followed by immersion in 98% formic acid (30 minutes) and were revealed using a biotinylated anti-PrP mAb (clone SAF83; kindly provided by J. Grassi, Commisariat à l'Energie Atomique, Fontenay-aux-Roses, France) and then horseradish peroxidase-conjugated streptavidin followed by H 2 O 2 /diaminobenzidin reaction. Frozen sections (5 µm) were fixed in acetone, rehydrated in PBS 0.5% BSA, and stained sequentially with biotinylated rat anti-mouse CD11c (PharMingen), streptavidin-cychrome5 (Jackson ImmunoResearch Laboratories Inc., West Grove, Pennsylvania, USA), FITC-conjugated rat anti-CD3, and phycoerythrin-conjugated rat anti-CD19 (PharMingen). Slides were analyzed using an LSM510 confocal microscope (Carl Zeiss, Esslingen, Germany).
Results
Scrapie infectivity in spleen cell fractions. Spleens were collected from C57BL/6 mice 10-13 weeks after intraperitoneal infection by the 139A scrapie strain, i.e., at a preclinical stage, and cell fractions were isolated as described above. Three spleen cell preparations were utilized as follows: a total mononuclear splenocyte population, a fraction enriched with CD11c/MHC class II(IAb)-positive cells corresponding to dendritic cells, and a B cell-enriched fraction. On a per cell basis, the infectivity titer found in the CD11c + dendritic cell fraction was more than 12-fold that found in the B cell-enriched fraction, and four to five times the titer found in the total mononuclear cell population ( 
Inoculation with total mononuclear spleen cells or CD11c + or B cell-enriched fractions induced scrapie in all recipients, except in one animal that had received the B cell-enriched preparation ( Table 2) . As expected, incubation times were shorter in animals that received total mononuclear spleen cells, given that they included both CD11c + dendritic cells and B cells together with other cell types, as well as a higher amount of infectious agent. None of five mice injected with frozen and thawed B cell lysates containing 10 4.9 infectious units of the same agent showed any signs of scrapie; three of these mice were sacrificed at 310 days, and two, at 407 days. Three mice injected with 10 5.7 infectious units in total mononuclear spleen cell lysates died of intercurrent infection after 232-269 days without signs of scrapie. These results merely confirm the known resistance of RAG-1 0/0 mice to peripheral inoculation with prions in cell lysates (6) and show that live spleen cells may, in certain conditions, transfer the disease. PrP Sc was detected in brains of all animals showing clinical signs of scrapie, including those that had received the B cell-and dendritic cell-enriched fractions and the total mononuclear spleen cells (Figure 1 ). None of those that had been injected with killed cells displayed detergent insoluble proteinase K-resistant PrP in the brain. Moreover, the diagnosis of scrapie was confirmed by passage into new mice (Table 3 titers of scrapie agent. Interestingly, in one RAG-1 0/0 mouse that had received infected dendritic cells and died of intercurrent infection before the clinical onset of scrapie, a lower but still strong level of brain infectivity was detected (incubation period after passage to CD-1 mice: 146 ± 1; n = 8). No infectivity was detected in the tested mouse that had been injected with killed infected total mononuclear spleen cells as of more than 200 days after infection (n = 8).
Immunological status of RAG-1 0/0 recipients. Importantly, no evidence of lymphoid reconstitution was detected in spleens from mice injected with CD11c + cells by histological and immunofluorescence criteria (Figure 2 ). Histological morphology was unequivocally identical to that of RAG-1 0/0 mice that had received killed cells, with a predominance of red pulp and some nonlymphoid nodules. On the other hand, mice injected with total mononuclear spleen cells or the B cell-enriched fraction had numerous lymphoid follicles in the spleen that stained for B and T cell markers, showing that B cell enrichment was only partial and that precursor cells of both lymphoid lineages were contained in the inoculum. As shown by immunochemical study after treatment in order to denature PrP C and enhance PrP Sc immunoreactivity (Figure 2, i and j) , prion protein was detected in the spleens of mice with lymphoid reconstitution but not in those that received the CD11c + dendritic cell fraction. This suggests that a replication
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The step in the spleen was involved in the former case but not after injection of infected dendritic cells alone.
Discussion
According to published data, mature B cells and, secondarily, germinal centers and FDC networks, are required for the development of clinical scrapie after peripheral injection using usual pathogenic doses (6 (6) . Given that CD11c + cells are present in spleens of nonreconstituted RAG-1 0/0 mice, there should be a certain requirement(s) for these cells to capture sufficient amounts of scrapie agent and allow neuroinvasion that are not fulfilled in the absence of lymphoid follicles. Such requirements might be the presence of mature FDCs, where prions could replicate before being delivered to dendritic cells. However, in certain conditions the scrapie agent seems able to reach the CNS without or with little help from FDCs: after intraperitoneal inoculation by usual doses, infectivity and proteaseresistant prion protein and spongiform changes were found in the brains of certain B cell/FDC-deficient mice in spite of the absence of clinical symptoms (6, 20) ; moreover, much higher doses injected in similar conditions provoked clinical disease in B cell/FDCdeficient mice (7) . Finally, certain models of FDC-deficient mice are susceptible to scrapie infection after peripheral inoculation (6, 8, 21) . The hypothesis of a participation of CD11c + dendritic cells in the process of neuroinvasion is compatible with what was observed when FDC maturation was suppressed by administration of LTβR-Ig: In these models, as stressed by Montrasio et al. (9) and Mabbott et al. (10) , impaired replication of scrapie agent at the periphery could be related not only to FDC but also to dendritic cell defect.
A role for CD11c + dendritic cells in the pathogenesis of transmissible spongiform encephalopathies in normal animals is supported by our finding of a comparatively high level of infectivity in this cell fraction. Fragments of FDC dendrites may have contaminated cell fractions and contributed to their infectivity; however, this would mainly concern B cells because of their close contacts with FDC networks; CD11c + dendritic cells, which predominate in T cell areas, were found to bear 12 times more infectious agent per cell. In accordance with this result, non-B/non-T stromal spleen cells from scrapie-infected mice were found to carry infectivity (22, 23) . Moreover, in scrapie-infected mice treated with LTβR-Ig, the pathological conformer of the prion protein (PrP Sc ) was shown to persist in the spleen in spite of the disappearance of mature FDCs (10) . PrP Sc aggregates might accumulate on the surface of FDC dendrites, from where they would be released to other cells permitting dissemination (12, 24) . Although other cells, such as tingible body macrophages (24) , are potential vectors of prion propagation from the lymphoid follicles, CD11c + dendritic cells are sufficient for neuroinvasion in RAG-1 0/0 recipients.
Although our adoptive transfer model in RAG-1 0/0 mice shows that dendritic cells are able to carry the scrapie agent from the vascular compartment to the CNS, the precise role of these cells in natural infection remains to be clarified.
The respective participation of FDCs and CD11c + dendritic cells might vary according to the conditions of infection and the route of neuroinvasion. It might also depend in part on the scrapie strains used, which would explain discrepancies observed in previous studies. The present results need to be confirmed with other prion strains. Using the 139A strain, we found that CD11c + dendritic cells collected from mice during the incubation period are able to carry the infection progressively to the CNS, without detectable accumulation in the spleen. Whether these cells replicate the scrapie agent, modify its nature, or acquire it passively, and how they interact directly or indirectly with nervous cells, remain to be established. A more complete understanding of the steps and the cells involved in prion spreading from the periphery to the brain may provide a pharmacological gatekeeper that could be used to stop the movement of infectivity.
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